Open access
Peer reviewed journal

Actual Gynecology
and Obstetrics


Cabergoline in prevention and treatment of ovarian hyperstimulation syndrome (article in Slovak)
Erik Dosedla, Petra Gašparová, Zuzana Ballová, Martina Sitáš, Zuzana Turcsányiová, Pavel Calda
Actual Gyn 2023, 15, 49-54
Publication date: 2023-06-29
Manuscript ID: 1523008
Počet zobrazení: 1991

Ovarian hyperstimulation syndrome, is considered to be rare, but even more serious iatrogenic complication of ovulation induction during assisted reproduction methods, associated with significant morbidity and potential mortality. Vascular endothelial growth factor plays a key role in the development of this syndrome, which leads to increased vascular permeability with the subsequent transfer of intravascular fluid into the compartments of the third space. Studies have shown that administration of dopamine agonists such as cabergoline blocks the increase in vascular permeability by dephosphorylation of vascular endothelial growth factor receptors. Cabergoline can thus be administered as an effective prevention of moderate and severe forms of ovarian hyperstimulation syndrome, as well as treatment of an already developed disease. However, there is still no standardized protocol according to which we should administer cabergoline.

Key words: ovarian hyperstimulation syndrome, dopamine agonist, cabergoline